Other languages Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
4.215 ^USD	-2.66%		+1.81%	-1.75%

May. 13	Sutro Biopharma Q1 Loss Widens, Revenue Rises	MT
May. 13	Earnings Flash (STRO) SUTRO BIOPHARMA Posts Q1 Revenue $13M	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sutro Biopharma Q1 Loss Widens, Revenue Rises	May. 13
Earnings Flash (STRO) SUTRO BIOPHARMA Posts Q1 Revenue $13M	May. 13
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones	May. 13
Sutro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13
BofA Securities Starts Sutro Biopharma With Buy Rating	May. 08
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial	Apr. 30
Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial	Apr. 30
Sutro Biopharma : Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – “Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more”	Apr. 04
Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	Apr. 03
Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating	Apr. 03
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering	Apr. 02
Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors	Apr. 02
Ipsen : accord de licence mondiale avec Sutro Biopharma	Apr. 02
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	Apr. 02
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	Mar. 26
Wedbush Adjusts Sutro Biopharma's Price Target to $8 From $12, Maintains Outperform Rating	Mar. 26
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones	Mar. 25
Sutro Biopharma to Participate in Upcoming Investor Conferences	Feb. 06
Transcript : Sutro Biopharma, Inc. - Special Call	Jan. 04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Other languages

Filters